Taipei Veterans Generla Hospital
Taipei, 112, Taiwan
NCT Number: NCT00755014
Light-to-moderate alcohol consumption has been associated with a reduction of cardiovascular events, and red wine seems to offer more benefits than any other type of alcoholic beverages. However, the relationship between red wine consumption and endothelial progenitor cells (EPCs) remains unclear. The investigators examine whether intake of red wine could enhance the number or functional capacity of circulating EPCs by upregulation of nitric oxide (NO) bioavailability.
Looking for future studies?
Notify Me20 year–40 year
All sexes
Interventional
Phase 1
Taipei, 112, Taiwan
Moderate ethanol intake from any type of beverage has been shown to improve lipoprotein metabolism and lower cardiovascular mortality risk, but red wine, with its abundant antioxidant contents, seems to confer additional healthy benefits. Previous studies indicated that the beneficial effects of red wine are derived from increased endothelium-derived nitric oxide (NO), implying that enhanced NO bioavailability may mediate the cardiovascular protection provided by red wine.
Increasing evidence suggests that the injured endothelial monolayer is regenerated partly by circulating bone marrow derived-endothelial progenitor cells (EPCs), which accelerate reendothelialization and protect against the initiation and progression of atherosclerosis. Clinical studies demonstrated that the number of circulating EPCs predicts the occurrence of cardiovascular events and death from cardiovascular causes and may help to identify patients at increased cardiovascular risk. Although many epidemiologic studies have indicated that light-to-moderate consumption of red wine can reduce the incidence of CAD, the multifarious effects of red wine on circulating EPCs and endothelial function remain to be determined. Therefore, we design this study to test the hypothesis that intake of red wine can enhance the number and functional capacity of EPCs through increasing NO bioavailability.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks
Other names: The red wine used is "Vin De Pays D'OC" (12.5% ethanol), a cabernet sauvignon from France, The beer used was Taiwan Beer (5% alcohol) from Taiwan.
Time frame: VGH-97DHA0100127
Time frame: VGH-97DHA0100127
Taipei Veterans General Hospital, Taiwan
Other Gov
Taipei Veterans General Hospital
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06890013
Acute Coronary Syndrome, Acute Coronary Syndromes
Thessaloniki, Greece
View Trial DetailsNCT06866119
Adnexal Diseases, Endocrine System Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT07245069
Anthracycline-induced Cardiac Toxicity, Arterial Stiffness
Ljubljana, Slovenia
View Trial DetailsNCT07244809
Adverse Childhood Experience, Endothelial Function (FMD)
Iowa City, Iowa, United States
View Trial Details